Hemafer

Hemafer is a prescription iron supplement whose active ingredient is iron (III) ion, supplied as an intramuscular injection. Although the exact strength is not specified, the product is marketed in the European Union for the treatment of iron deficiency. It belongs to the drug class of iron supplements (ATC code B03A) and is intended for patients who require parenteral iron replacement as part of their therapy regimen.

Hemafer is indicated for the management of iron deficiency anemia when oral iron therapy is ineffective, not tolerated, or when rapid repletion of iron stores is required.

- Iron deficiency anemia in adults. - Anemia associated with chronic kidney disease. - Pre‑operative anemia correction. - Anemia in patients with gastrointestinal malabsorption. - Situations requiring rapid increase of hemoglobin before chemotherapy. - Anemia in pregnant women when oral iron is contraindicated.

The safety profile of Hemafer reflects the typical adverse events associated with parenteral iron preparations, ranging from mild, transient reactions to rare but serious complications.

Common: - Pain, redness, or swelling at the injection site lasting a few hours. - Mild headache that resolves without treatment. - Nausea or transient gastrointestinal discomfort such as mild abdominal cramping. - Low‑grade fever or chills occurring within 24 hours after injection.

Serious: - Severe allergic reaction (anaphylaxis) characterized by difficulty breathing, rash, or swelling of the face. - Sudden drop in blood pressure (hypotension) or shock requiring medical attention. - Iron overload leading to organ dysfunction, particularly liver or cardiac involvement. - Acute hemolysis presenting with dark urine, jaundice, or rapid decline in hemoglobin.

Before prescribing Hemafer, clinicians should evaluate patient history and clinical status to minimize risks and ensure appropriate use.

- Known hypersensitivity to iron preparations or any component of the injection. - Active infections, especially systemic bacterial infections, due to risk of exacerbation. - History of severe allergic reactions or anaphylaxis to parenteral drugs. - Pre‑existing iron overload conditions such as hemochromatosis. - Uncontrolled hypertension or cardiovascular instability. - Pregnancy and lactation status, as safety data are limited.

Hemafer may interact with other medicines, affecting iron absorption, distribution, or the risk of adverse reactions.

Avoid: - Concurrent use of high‑dose oral iron supplements, which can increase iron load. - Intravenous or intramuscular administration of other iron formulations within 24 hours.

Use with caution: - Antacids or oral chelating agents that may reduce iron availability. - Certain antibiotics (e.g., tetracyclines, quinolones) that can form complexes with iron. - Levothyroxine, as iron may impair its absorption if taken simultaneously.